Zobrazeno 1 - 10
of 304
pro vyhledávání: '"Gregory B Lesinski"'
Autor:
Gregory B Lesinski, Chrystal M Paulos, Hannah M Knochelmann, Megan M Wyatt, Guillermo O Rangel Rivera, Anna C Cole, Megen C Wittling
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 6 (2024)
Background How distinct methods of host preconditioning impact the efficacy of adoptively transferred antitumor T helper cells is unknown.Methods CD4+ T cells with a transgenic T-cell receptor that recognize tyrosinase-related peptide (TRP)-1 melanom
Externí odkaz:
https://doaj.org/article/fe2e22541bba40599235ed797c618c73
Autor:
Yuan Liu, Gregory B Lesinski, Chrystal M Paulos, Shishir Maithel, Brian Robinson, Megan M Wyatt, Jacklyn Hammons, Emilie AK Warren, Jessica Keilson, Guillermo O Rangel-Rivera, Caroline R Goel, Curtis J Henry, Sarah Kulkarni, Alyssa Krasinskas
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/37367ff22182415cbee2fec23e4ef72b
Autor:
Gregory B Lesinski, Chrystal M Paulos, Cameron Herting, Maggie Phillips, Megan M Wyatt, Natalie K Horvat, Jacklyn Hammons, Isaac Karpovsky, Zaid Mahdi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/f6ca546f1adc4d1baaa7f6c51003c403
Autor:
Brian Burns, Elizabeth Evans, Ragini Kudchadkar, Crystal Mallow, Christine Reilly, Maurice Zauderer, Gregory B Lesinski, Keith A Delman, Chrystal M Paulos, Brian Olson, Terrence Fisher, Jayden Kim, Michael C Lowe, Ayana T Ruffin, Jacklyn Hammons, Agnes Harutyunyan, Melinda Yushak, Ali Mokhtari, Douglas Parker
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/8b6f56ca06554f4e801dde08a7b6b1a3
Autor:
Thomas Mace, Gregory B Lesinski, Chrystal M Paulos, Michael Ware, Olatunji Alese, Juan Sarmiento, Shishir Maithel, Maggie Phillips, Megan M Wyatt, Natalie K Horvat, Jacklyn Hammons, Bassel FEl Reyes
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/ec528f048f7847a9b25e2cd153a50053
Autor:
Gregory B Lesinski, Chrystal M Paulos, Bhavana Pavuluri, Aubrey S Smith, Hannah M Knochelmann, Megan M Wyatt, Guillermo O Rangel Rivera, Amalia M Rivera-Reyes, Anna C Cole, Soundharya Kumaresan, Megen Wittling, Ayana T Ruffin, Jeremy M Boss
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/3d6aeccb47f34c11a138d5d5f733aafd
Autor:
Gregory B Lesinski, Keith A Delman, Chrystal M Paulos, Hannah M Knochelmann, Megan M Wyatt, Michael C Lowe, Soundharya Kumaresan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/9c2bf307fae94d6eb4466f9d484f1ccf
Autor:
Gregory B Lesinski, Christina Wu, Mehmet Akce, Brian Olson, Maria Diab, Batoul Farran, Jeffrey M Switchenko, Manali Rupji, Sandra Kang, Lana Khalil, Amanda Ruggieri-Joyce, Walid L Shaib, Olatunji B Alese, Bassel F El-Rayes
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Background Preclinical studies showed metformin reduces exhaustion of tumor-infiltrating lymphocytes and potentiates programmed cell death protein-1 (PD-1) blockade. We hypothesized that metformin with nivolumab would elicit potent antitumor and immu
Externí odkaz:
https://doaj.org/article/2bc4352546204629923aab3d10545a4e
Autor:
Chrystal Paulos, Gregory B Lesinski, Zachary S Buchwald, Nabil F Saba, Vikash Kansal, Andre J Burnham, Brendan L C Kinney, Nicole C Schmitt
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 1 (2023)
Background Anti-PD-1 immune checkpoint blockade is approved for first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), but few patients respond. Statin drugs (HMG-CoA reductase inhibitors) are associated with supe
Externí odkaz:
https://doaj.org/article/8c89bacdb70947e88cb21a0488441844
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Pancreatic ductal adenocarcinoma (PDAC) is plagued by a dismal 5-year survival rate, early onset of metastasis and limited efficacy of systemic therapies. This scenario highlights the need to fervently pursue novel therapeutic strategies to treat thi
Externí odkaz:
https://doaj.org/article/a3e632be96e54b3ba4ebfcfc5408ed7d